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Clinical question: Which antidiabetic drugs provide optimal weight control in patients with 
type 2 diabetes?
Results: Metformin reduces weight gain, and may cause weight loss, when given alone or in 
combination with other drugs. Pioglitazone and rosiglitazone use is associated with weight gain. Use 
of the glucagon-like peptide-1 (GLP-1) analogs, liraglutide and exenatide, is associated with weight 
loss. Dipeptidyl peptidase-4 (DPP-4) inhibitors are considered weight-neutral. Results with insulin 
therapy are conflicting. Insulin detemir provides weight control along with glycemic control.
Implementation: 
•	 Weight gain is considered an inevitable part of good glycemic control using conventional 
modalities of treatment such as sulfonylureas.1
•	 Use of metformin, weight-sparing insulin analogs such as insulin detemir, and liraglutide, 
should be encouraged as monotherapy, or in combination with other drugs.
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Weight control in diabetes
Definition: Weight control is an important aspect of diabetes treatment, and can 
improve glycemic control and cardiovascular risk factors per se.1,2 The term “diabesity” 
is used to define the pathogenic relationship between diabetes and obesity.3
Incidence: Glycemic control using conventional drugs is usually associated with 
weight gain.3 A head-to-head comparison of various treatment modalities regarding 
the incidence of weight gain has not been done.
Economics: No published study has addressed the direct cost of weight gain during 
diabetes treatment. However, weight loss has been shown to reduce medical and 
pharmaceutical costs in patients with diabetes.4 Drugs which are relatively more cost-
effective, such as sulfonylureas, may not end up being cheaper if they increase the 
overall costs of therapy, and studies are needed to address this issue.
Level of evidence: Systemic reviews, meta-analysis, randomized controlled trials, 
guidelines.
Search sources: PubMed, Cochrane Library, Google Scholar.
Outcomes: Both physicians and patients seek:
1.  Minimum weight gain in patients of normal weight
2.  Weight loss in overweight patientsDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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The evidence
Do antidiabetic drugs increase  
or decrease weight?
Systematic reviews:   . 10
Meta-analyses:     . 10
Randomized controlled trials: . 100 have been published.
Systematic reviews5,6 and meta-analysis have concluded 
that pioglitazone and rosiglitazone lead to weight gain. The 
combined use of metformin and the thiazolidinediones shows 
controversial results related to weight gain.
Sulfonylurea use is linked to significant weight gain.7 
Addition of sulfonylureas to metformin is also associated 
with weight gain, but to a lesser degree, according to meta-
analysis.8 A meta-analysis has shown that a combination of 
sulfonylureas and insulin does not lead to weight gain.9
Metformin has been shown to reduce weight, as compared 
with sulfonylureas, in meta-analysis.10 Metformin, when 
The practice
used as cotherapy, also mitigates the weight gain seen with 
sulfonylureas and repaglinide.11
Alpha-glucosidase inhibitors have an insignificant 
effect on weight, as per a meta-analysis of 41 studies.12 
A randomized controlled trial shows that voglibose 
coadministration can reduce the weight gain associated 
with pioglitazone use.13
Other meta-analysis shows that the DPP-4 inhibitors, such 
as vildagliptin and sitagliptin, are weight-neutral,14 while the 
GLP-1 analogs, ie, liraglutide and exenatide, are associated 
with weight loss.
Insulin detemir is the only insulin to show weight 
loss or reduced weight gain consistently in overweight 
patients in meta-analysis.15 Results with other insulin 
preparations are conflicting.16 Insulin glargine use causes 
more weight gain than Neutral Protamine Hagedorn 
insulin.17
Potential pitfalls
•	 Weight control and glycemic control should be aimed for
•	 Weight gain may mitigate the benefits achieved by 
glycemic control
•	 Try to combine regimes with metformin, but keep a watch 
for contraindications and side effects of metformin
•	 Avoid using a combination of medications which cause 
weight gain
•	 Avoid overdosage of insulin, which may lead to weight 
gain by causing hypoglycemia and increased snacking.
Management
•	 Reinforce diet and physical activity as effective methods 
of glycemic and weight control1
•	 Optimal choice of antidiabetic drugs can help avoid 
excessive weight gain5
•	 Specialist referral will rarely be needed to optimize weight 
control.
Assessment
•	 Measure weight, waist and hip circumference, and watch 
for edema regularly in all patients with diabetes
•	 Presence of edema or waist gain should prompt a review 
of antidiabetic, as well as other, medications.
Treatment
•	 If possible, discontinue or replace thiazolidinediones if 
excessive weight gain occurs with their use, or is to be 
avoided
•	 Reduce the dose of insulin, especially rapid-acting insulin 
if patients complain of excessive weight gain associated 
with hypoglycemia
•	 Shift to insulin detemir if indicated
•	 Add/increase the dose of metformin, to maximally 
tolerated levels
•	 Use GLP-1 analogs, such as liraglutide and exenatide, if 
weight gain is an issue.
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